EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Standardized Production of Anti‐Desmoglein 3 Antibody AK23 for Translational Pemphigus Vulgaris Research

Eliane J Mueller, Siavash Rahimi iD, Patrizia Sauta, Taravat Shojaeian, Laurence Durrer, Soraya Quinche, Michael Francois, Elisabeth Locher, Monika Edler, Marlies Illi, Thomas Gentinetta, Kelvin Lau und 3 weitere

Current Protocols · 2024

DOI: 10.1002/cpz1.1118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Protocols, 2024. Verfasst von Eliane J Mueller und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department for Biomedical Research, Molecular Dermatology and Stem Cell Research, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Pemphigus, Desmoglein 3. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody‐mediated receptor activation is successfully used to develop medical treatments. If the activation induces a pathological response, such antibodies are also excellent tools for defining molecular mechanisms of target receptor malfunction and designing rescue therapies. Prominent examples are naturally occurring autoantibodies inducing the severe blistering disease pemphigus vulgaris (PV). In the great majority of patients, the antibodies bind to the adhesion receptor desmoglein 3 (Dsg3) and interfere with cell signaling to provoke severe blistering in the mucous membranes and/or skin. The identification of a comprehensive causative signaling network downstream of antibody‐targeted Dsg3 receptors (e.g., shown by pharmacological activators or inhibitors) is currently being discussed as a basis to develop urgently needed first‐line treatments for PV patients. Although polyclonal PV IgG antibodies have been used as proof of principle for pathological signal activation, monospecific anti‐Dsg3 antibodies are necessary and have been developed to identify pathological Dsg3 receptor–mediated signal transduction. The experimental monospecific PV antibody AK23, produced from hybridoma cells, was extensively tested in our laboratory in both in vitro and in vivo models for PV and proved to recapitulate the clinicopathological features of PV when generated using the standardized production and purification protocols described herein. © 2024 The Author(s). Current Protocols published by Wiley Periodicals LLC. This article was corrected on 18 November 2025. See the end of the full text for details. Basic Protocol 1 : Bovine IgG stripping from FBS and quality control Basic Protocol 2 : AK23 hybridoma expansion and IgG production Basic Protocol 3 : AK23 IgG purification Basic Protocol 4 : AK23 IgG quality control Support Protocol 1 : Detection of endotoxin levels Support Protocol 2 : Detection and removal of mycoplasma

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PemphigusDesmoglein 3AnimalsHumansMiceAutoantibodiesTranslational Research, Biomedical

Stichwörter der Autor:innen

PVPV IgGexperimental pemphigus vulgaris (PV) antibody AK23signal transduction

Substanzen

Desmoglein 3Autoantibodies

Autor:innen und Institutionen

  • Department for Biomedical Research, Molecular Dermatology and Stem Cell Research, University of Bern, Bern, Switzerland.
  • Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • DermFocus, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Protein Production and Structure Core Facility, School of Life Sciences, EPFL Lausanne, Lausanne, Switzerland.
  • CSL, CSL Biologics Research Centre, Bern, Switzerland.
  • Swiss Institute for Translational and Entrepreneurial Medicine, sitem-insel, Bern, Switzerland.

ORCID-Profile: Siavash Rahimi, William V J Hariton

Zitieren

APA

Mueller, E. J., Rahimi, S., Sauta, P., Shojaeian, T., Durrer, L., Quinche, S., Francois, M., Locher, E., Edler, M., Illi, M., Gentinetta, T., Lau, K., Pojer, F., Borradori, L., & Hariton, W. V. J. (2024). Standardized Production of Anti‐Desmoglein 3 Antibody AK23 for Translational Pemphigus Vulgaris Research. Current Protocols. https://doi.org/10.1002/cpz1.1118

Vancouver

Mueller EJ, Rahimi S, Sauta P, Shojaeian T, Durrer L, Quinche S, et al. Standardized Production of Anti‐Desmoglein 3 Antibody AK23 for Translational Pemphigus Vulgaris Research. Current Protocols. 2024. doi:10.1002/cpz1.1118

BibTeX
@article{Mueller2024,
  author = {Mueller, Eliane J and Rahimi, Siavash and Sauta, Patrizia and Shojaeian, Taravat and Durrer, Laurence and Quinche, Soraya and Francois, Michael and Locher, Elisabeth and Edler, Monika and Illi, Marlies and Gentinetta, Thomas and Lau, Kelvin and Pojer, Florence and Borradori, Luca and Hariton, William V J},
  title = {Standardized Production of Anti‐Desmoglein 3 Antibody AK23 for Translational Pemphigus Vulgaris Research},
  journal = {Current Protocols},
  year = {2024},
  doi = {10.1002/cpz1.1118}
}
Kostenlos starten →